Latest1 information on COVID-19
©2022 Stanford Medicine
Gilead Sustained Virologic Response (SVR) Registry
Not Recruiting
Trial ID: NCT01457755
Purpose
This Registry is designed to provide long term clinical and virologic follow up in
participants who have achieved sustained virologic response (SVR) while participating in a
previous Gilead sponsored hepatitis C virus (HCV) study. This long term follow up study is
observational and no treatment is provided for HCV.
Official Title
A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection
Stanford Investigator(s)
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Eligibility
Key Inclusion Criteria:
- Have previously participated in a Gilead-sponsored hepatitis C study and received at
least one Gilead oral antiviral agent (OAV)
- Have achieved SVR in a Gilead-sponsored study, as defined in the original treatment
protocol
- Provide written, informed consent
- Be willing and able to comply with the visit schedule and protocol-mandated procedures
Key Exclusion Criteria:
- Individuals planning to start a new course of hepatitis C therapy including any
investigational drug or device during the course of the follow-up Registry
- History of clinically significant illness or any other major medical disorder that may
interfere with follow up, assessments, or compliance with the protocol
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mindie H. Nguyen, MD
650-498-7878